Throughout his 20-year career, David Venderbush, has always been at the heart of bet-the-company litigations literally ripped from the headlines. In litigations involving breast implants, asbestos, cell phones, Vioxx, Seroquel, and unintended automobile acceleration, Mr. Venderbush’s work in various virtual law firms has helped reduce eventual client expense to a fraction of initial potential exposure.
As counsel in the Products Liability Group, Mr. Venderbush focuses his practice on trial and appellate work, with particular expertise in legal strategies for managing complex litigation. As a member of national counsel teams in several multidistrict litigations, he has served as national litigation strategist, supervised local counsel and implemented litigation management and expense control programs. Mr. Venderbush has been particularly successful at effectively ending mass tort litigations through the exclusion of expert witness testimony on complex scientific issues under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). He is well known among his peers for his legal analysis and brief-writing abilities.
Mr. Venderbush has participated in several high-profile trials, managing legal issues and trial briefing and has argued to federal and state appellate courts. He is a five-time Jeopardy! champion.
Mr. Venderbush has successfully excluded the testimony of numerous expert witnesses following Rule 702 evidentiary hearings in a variety of contexts:
- Silicone breast implants: (Hall v. Baxter Healthcare Corp., 947 F. Supp. 1387 (D. Or. 1996); In re Breast Implant Litigation, 11 F. Supp. 2d 1217 (D. Colo. 1998); Kelley v. American Heyer-Schulte Corp., 957 F. Supp. 873 (W.D. Tex. 1997)).
- Mobile telephones: (Newman v. Motorola, Inc., 218 F. Supp. 2d 769 (D. Md. 2002), aff'd 78 Fed. Appx. 292 (4th Cir. 2003)).
- Uranium ore: (Cano v. Everest Minerals Corp., 362 F. Supp. 2d 814 (W.D. Tex. 2005)).
- Pharmaceuticals: (Guinn v. AstraZeneca Pharms. LP, 602 F.3d 1245 (11th Cir. 2010); Haller v. AstraZeneca Pharms. LP, 598 F. Supp. 2d 1271 (M.D. Fla. 2009); Scaife v. AstraZeneca LP, 2009 WL 1610575 (Del. Super. Ct. June 9, 2009)).